AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

HBM Healthcare Investments AG

Share Issue/Capital Change Oct 14, 2024

893_rns_2024-10-14_5e325557-664d-435c-ab43-8edc9b0e74f6.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

News Details

Corporate | 14 October 2024 06:30

HBM portfolio company Upstream Bio raises USD 255 million in successful initial public offering

HBM Healthcare Investments AG / Key word(s): IPO

HBM portfolio company Upstream Bio raises USD 255 million in successful initial public offering

14.10.2024 / 06:30 CET/CEST

Upstream Bio (Nasdaq: UPB), a previously private company in the HBM Healthcare Investments portfolio, got off to a successful start on the stock market last Friday. The company raised USD 255 million in new capital through the issuance of 15 million shares at a price of USD 17.00 per share. The share price rose to USD 22.00 (+29.4%) on the first day of trading, valuing the company at around USD 1.1 billion.

HBM Healthcare Investments has invested a total of USD 30 million in two financing rounds of Upstream Bio since October 2021. Most recently, the investment was valued at USD 44 million. Following the IPO, HBM Healthcare Investments holds approximately 2.7 million shares with a total value of USD 59.7 million.

Upstream Bio is a biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company is developing verekitug, a unique antibody that targets the receptor for thymic stromal lymphopoietin (TSLP), a key driver of inflammation. Verekitug is currently in Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps, and the company plans to explore its use in chronic obstructive pulmonary disease (COPD).

Contact

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at [email protected] .


End of Media Release


Language: English
Company: HBM Healthcare Investments AG
Bundesplatz 1
6300 Zug
Switzerland
Phone: +41438887171
Fax: +41438887172
E-mail: [email protected]
Internet: https://www.hbmhealthcare.com
ISIN: CH0012627250
Valor: 1262725
Listed: SIX Swiss Exchange
EQS News ID: 2007323
End of News EQS News Service

show this

Talk to a Data Expert

Have a question? We'll get back to you promptly.